EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | A212689 | ZYDUS PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
GILEAD SCIENCES, INC. et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al 6 patentsANDA 212689emtricitabine and tenofovir disoproxil fumarate | D.N.J. | 2019-01-15 | Terminated 2019-08-28 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$10.19
per ea
Lowest NADAC/Unit
$0.4566
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70710136403EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB | $10.19 | EA | Generic | — | 2026-04-22 |
| 70710136703EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | $0.4566 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.